Streetbeat News

Products Services

F

RIVN

SPY

TSLA

Tesla's Cybertruck, set to launch in 2023, has garnered significant attention and is expected to compete with legacy automakers in the pickup truck market. Since its unveiling in November 2019, a $1,000 investment in Tesla stock would have grown to $8,425.75, a 742.6% increase.

Portfolio Pulse from Chris Katje

May 23, 2023 | 6:27 pm

AZN

AstraZeneca presented positive data on its BREZTRI treatment for chronic obstructive pulmonary disease (COPD) at the ATS 2023 conference. The results show improved lung function and reduced exacerbations in patients.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 6:21 pm

NFLX

Netflix is offering U.S. members the option to add an extra member to their account for $7.99/month, allowing them to share their account with someone who doesn't live with them.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 6:20 pm

GENE

Genetic Technologies has been granted Canadian Patent Number 2962691 for its methods of assessing the risk of developing breast cancer. This patent could potentially expand the company's market reach.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 6:11 pm

NFLX

Netflix will begin sending emails to members sharing their accounts outside their household in the United States starting Tuesday, as part of an effort to curb unauthorized account sharing.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 6:07 pm

DELL

NVDA

Dell Technologies and NVIDIA have announced a collaboration to launch Project Helix, aimed at assisting enterprises in building and deploying reliable, on-premises generative AI. The initiative will offer full-stack solutions with technical expertise and pre-built tools. Project Helix will be available from July 2023.

Portfolio Pulse from Lekha Gupta

May 23, 2023 | 6:02 pm

SGHT

Sight Sciences published two-year results of the Romeo study of the OMNI Surgical System, showing consistent lowering of eye pressure and medication use in cataract surgery. The study observed no serious or unanticipated adverse events during the two-year period.

Portfolio Pulse from Vandana Singh

May 23, 2023 | 6:00 pm

BPMC

The FDA has approved Blueprint Medicines Corporation's (NASDAQ:BPMC) Ayvakit for the treatment of adults with indolent systemic mastocytosis (ISM). Ayvakit has been FDA-approved for advanced SM since June 2021. In Q1 2023, Blueprint Medicines reported Ayvakit sales of $39.1 million, up from $23.8 million a year ago.

Portfolio Pulse from Vandana Singh

May 23, 2023 | 5:55 pm

MREO

Mereo BioPharma presented Phase 2 data from the ASTRAEUS trial of alvelestat for Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) at the 2023 American Thoracic Society International Conference. The data showed significant biomarker reductions and Mereo is preparing for a pivotal Phase 3 study.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 5:45 pm

ARWR

Arrowhead Pharmaceuticals presented interim data from its Phase 2 GATEWAY study of ARO-ANG3, an RNAi therapeutic for homozygous familial hypercholesterolemia (HoFH). The company plans to initiate a Phase 3 study and meet with regulatory authorities in 2H 2023.

Portfolio Pulse from Vandana Singh

May 23, 2023 | 5:41 pm